Cerebral subcortical small vessel disease in subjects with pathologically confirmed alzheimer disease: A clinicopathologic study in the oxford project to investigate memory and ageing (OPTIMA) by Esiri, M, Joachim, C, Sloan, C, Christie, S, Agacinski, G, Bridges, L, Wilcock, G, Smith, A

“…A previous study from the Oxford Project to Investigate Memory and Ageing (OPTIMA) validated a scheme for assessing the contribution of subcortical small vessel disease (SVD) toward dementia in the elderly by showing a significant inverse relationship between the severity of SVD and cognition in subjects without any other dementia pathology using this method. …”

Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: a clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA). by Esiri, M, Joachim, C, Sloan, C, Christie, S, Agacinski, G, Bridges, L, Wilcock, G, Smith, A

“…A previous study from the Oxford Project to Investigate Memory and Ageing (OPTIMA) validated a scheme for assessing the contribution of subcortical small vessel disease (SVD) toward dementia in the elderly by showing a significant inverse relationship between the severity of SVD and cognition in subjects without any other dementia pathology using this method. …”

Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. by Esiri, M, Chance, S, Joachim, C, Warden, D, Smallwood, A, Sloan, C, Christie, S, Wilcock, G, Smith, A

“…In this article, the literature on this subject is reviewed and novel findings relating CAA to subcortical white matter damage in 224 subjects in the Oxford project to Investigate Memory and Ageing (OPTIMA) are reported. The relationship between CAA and subcortical tissue damage in the OPTIMA subjects was found to be critically dependent on ApoE genotype, there being a positive relationship between measures of CAA and subcortical small vessel disease in ApoEε4 carriers and a significant negative relationship in ApoEε2 carriers. …”

The effects of two polymorphisms on p21cip1 function and their association with Alzheimer's disease in a population of European descent by Yates, S, Zafar, A, Rabai, E, Foxall, J, Nagy, S, Morrison, K, Clarke, C, Esiri, M, Christie, S, Smith, A, Nagy, Z

“…The genotyping studies were performed on 719 participants of the Oxford Project to Investigate Memory and Ageing, 225 participants of a Parkinson's disease DNA bank, and 477 participants of the Human Random Control collection available from the European Collection of Cell Cultures. …”

Population-based case-control study of white matter changes on brain imaging in transient ischemic attack and ischemic stroke by Li, L, Simoni, M, Küker, W, Schulz, U, Christie, S, Wilcock, G, Rothwell, P

“…Methods: We evaluated the presence and severity of WMC on computed tomography and on magnetic resonance brain imaging using modified Blennow/Fazekas scale and age-related white matter changes scale, respectively, in a populationbased study of patients with incident transient ischemic attack or ischemic stroke (Oxford Vascular Study) and in a study of local controls (Oxford Project to Investigate Memory and Ageing) without history of transient ischemic attack or ischemic stroke, with stratification by stroke pathogenesis (Trial of Org10172 in Acute Stroke Treatment classification). …”

Population-based case-control study of white matter changes on brain imaging in transient ischemic attack and ischemic stroke. by Li, L, Simoni, M, Küker, W, Schulz, U, Christie, S, Wilcock, G, Rothwell, P

“…METHODS: We evaluated the presence and severity of WMC on computed tomography and on magnetic resonance brain imaging using modified Blennow/Fazekas scale and age-related white matter changes scale, respectively, in a population-based study of patients with incident transient ischemic attack or ischemic stroke (Oxford Vascular Study) and in a study of local controls (Oxford Project to Investigate Memory and Ageing) without history of transient ischemic attack or ischemic stroke, with stratification by stroke pathogenesis (Trial of Org10172 in Acute Stroke Treatment classification). …”